Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of the Efficacy and Safety of ORC-13661 for the Prevention of Drug-Induced Hearing Loss in Patients Receiving Intravenous Amikacin Therapy for Non-Tuberculous Mycobacterium Disease

NCT05730283 is registered in ClinicalTrials.gov with Kevin Winthrop as lead sponsor.

NCT NCT05730283
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05730283 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of the Efficacy and Safety of ORC-13661 for the Prevention of Drug-Induced Hearing Loss in Patients Receiving Intravenous Amikacin Therapy for Non-Tuberculous Mycobacterium Disease
Lead sponsor
Kevin Winthrop
Phase
Phase 2
Overall status
Recruiting
Start date
June 2, 2025
Completion date
February 29, 2028
Enrollment
105 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

ototoxicity, drug-induced